The Full Wiki

More info on LILRA2

LILRA2: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2
Symbols LILRA2; CD85H; ILT1; LIR-7; LIR7
External IDs OMIM604812 HomoloGene68534 GeneCards: LILRA2 Gene
RNA expression pattern
PBB GE LILRA2 207857 at tn.png
PBB GE LILRA2 211100 x at tn.png
PBB GE LILRA2 211101 x at tn.png
More reference expression data
Species Human Mouse
Entrez 11027 n/a
Ensembl ENSG00000187095 n/a
UniProt Q8N149 n/a
RefSeq (mRNA) NM_006866 n/a
RefSeq (protein) NP_006857 n/a
Location (UCSC) Chr 19:
59.78 - 59.79 Mb
PubMed search [1] n/a

Leukocyte immunoglobulin-like receptor subfamily A member 2 is a protein that in humans is encoded by the LILRA2 gene.[1][2][3]

Leukocyte Ig-like receptors (LIRs) are a family of immunoreceptors expressed predominantly on monocytes and B cells and at lower levels on dendritic cells and natural killer (NK) cells. All LIRs in subfamily B have an inhibitory function (see, e.g., LILRB1, MIM 604811). LIRs in subfamily A, with short cytoplasmic domains lacking an immunoreceptor tyrosine-based inhibitory motif (ITIM) and with transmembrane regions containing a charged arginine residue, may initiate stimulatory cascades. One member of subfamily A (LILRA3; MIM 604818) lacks a transmembrane region and is presumed to be a soluble receptor.[supplied by OMIM][3]


See also


  1. ^ Samaridis J, Colonna M (Apr 1997). "Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways". Eur J Immunol 27 (3): 660-5. PMID 9079806.  
  2. ^ Borges L, Hsu ML, Fanger N, Kubin M, Cosman D (Apr 1998). "A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules". J Immunol 159 (11): 5192-6. PMID 9548455.  
  3. ^ a b "Entrez Gene: LILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2".  

Further reading

  • Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.  
  • Rojo S, Burshtyn DN, Long EO, Wagtmann N (1997). "Type I transmembrane receptor with inhibitory function in mouse mast cells and NK cells.". J. Immunol. 158 (1): 9–12. PMID 8977169.  
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.  
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.  
  • Tedla N, Bandeira-Melo C, Tassinari P, et al. (2003). "Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7.". Proc. Natl. Acad. Sci. U.S.A. 100 (3): 1174–9. doi:10.1073/pnas.0337567100. PMID 12529506.  
  • Nakajima H, Asai A, Okada A, et al. (2004). "Transcriptional regulation of ILT family receptors.". J. Immunol. 171 (12): 6611–20. PMID 14662864.  
  • Sloane DE, Tedla N, Awoniyi M, et al. (2004). "Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition.". Blood 104 (9): 2832–9. doi:10.1182/blood-2004-01-0268. PMID 15242876.  
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334.  

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.



Got something to say? Make a comment.
Your name
Your email address